Penta ID Innovation and CROMSOURCE announced their partnership focused on improving drug development for pediatric patients.
The collaboration combines Penta's expertise in pediatric infectious diseases and CROMSOURCE's capabilities in managing worldwide drug development programs to address the challenges of bringing new therapies to children.
"We are thrilled to partner with such a prestigious and dynamic organization," said Oriana Zerbini, CEO of CROMSOURCE. "The partnership will enable us to share scientific, therapeutic, regulatory and operational expertise, creating a high-quality, highly scalable clinical development capability for paediatric research. Our strategic partnership will accelerate the availability of new products to address unmet medical needs of children around the world."
"CROMSOURCE is an ideal partner for Penta ID Innovation because of its proven track record of quality in addition to its attention to detail and commitment to delivery of services at every phase of clinical development,” Penta ID Innovation CEO, Luigi Comacchio, said.